Centessa Pharmaceuticals plc 8-K — AI Bull & Bear Analysis

Centessa Pharmaceuticals has reached a critical juncture in its merger with Eli Lilly following the expiration of the HSR Act waiting period. While this removes a primary regulatory obstacle, the deal's completion still hinges on court approval and shareholder consent. The market is now shifting its focus from antitrust risk to execution risk, as investors weigh the certainty of a pharmaceutical giant's buyout against the remaining legal and procedural requirements of a court-sanctioned scheme of arrangement.